Cargando…

Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience

OBJECTIVE: To evaluate the clinical spectrum of diffuse parenchymal lung diseases (DPLD) encountered in the Indian setting and to compare idiopathic pulmonary fibrosis (IPF) and connective tissue disease associated DPLD (CTD-DPLD), the two commonest aetiologies. MATERIALS AND METHODS: A prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Kundu, Somenath, Mitra, Subhra, Ganguly, Joydeep, Mukherjee, Subhasis, Ray, Souvik, Mitra, Ritabrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220317/
https://www.ncbi.nlm.nih.gov/pubmed/25378843
http://dx.doi.org/10.4103/0970-2113.142115
_version_ 1782342713218170880
author Kundu, Somenath
Mitra, Subhra
Ganguly, Joydeep
Mukherjee, Subhasis
Ray, Souvik
Mitra, Ritabrata
author_facet Kundu, Somenath
Mitra, Subhra
Ganguly, Joydeep
Mukherjee, Subhasis
Ray, Souvik
Mitra, Ritabrata
author_sort Kundu, Somenath
collection PubMed
description OBJECTIVE: To evaluate the clinical spectrum of diffuse parenchymal lung diseases (DPLD) encountered in the Indian setting and to compare idiopathic pulmonary fibrosis (IPF) and connective tissue disease associated DPLD (CTD-DPLD), the two commonest aetiologies. MATERIALS AND METHODS: A prospective study of clinical, imaging and laboratory parameters of patients diagnosed as DPLD and followed up in the Pulmonary Medicine Department of a tertiary-care teaching institution in eastern India was conducted over a period of one year. RESULTS: 92 patients of DPLD were diagnosed in the study period with IPF (n = 35, 38.04%), CTD-DPLD (n = 29, 31.5%), hypersensitivity pneumonitis (n = 10, 10.9%), sarcoidosis (n = 5, 5.4%) and silicosis (n = 5, 5.4%) being the common causes. The CTD-DPLD group had a lower mean age (39.5 ± 1.86 vs 56.9 ± 1.12 years), a longer duration of symptoms (3.5 ± 0.27 vs 2.5 ± 0.26 years), more extra pulmonary manifestations, significantly more base line FVC and 6-minute-walk-distance than the IPF patients. 19 patients of IPF (54%) opted for treatment. All the IPF patients had a significant fall in FVC after six months (mean change -0.203 ± 0.01 litres) compared to the CTD-DPLD group (mean change - 0.05 ± 0.04 litres.) CONCLUSION: CTD-DPLD patients belong to a younger age group, with longer duration of symptoms, more extrapulmonary features, better physiological parameters and better response to therapy than IPF patients. Larger prospective epidemiological studies and enrolment in clinical trials are necessary for better understanding of the spectrum of diffuse parenchymal lung disorders and their therapeutic options.
format Online
Article
Text
id pubmed-4220317
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42203172014-11-06 Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience Kundu, Somenath Mitra, Subhra Ganguly, Joydeep Mukherjee, Subhasis Ray, Souvik Mitra, Ritabrata Lung India Original Article OBJECTIVE: To evaluate the clinical spectrum of diffuse parenchymal lung diseases (DPLD) encountered in the Indian setting and to compare idiopathic pulmonary fibrosis (IPF) and connective tissue disease associated DPLD (CTD-DPLD), the two commonest aetiologies. MATERIALS AND METHODS: A prospective study of clinical, imaging and laboratory parameters of patients diagnosed as DPLD and followed up in the Pulmonary Medicine Department of a tertiary-care teaching institution in eastern India was conducted over a period of one year. RESULTS: 92 patients of DPLD were diagnosed in the study period with IPF (n = 35, 38.04%), CTD-DPLD (n = 29, 31.5%), hypersensitivity pneumonitis (n = 10, 10.9%), sarcoidosis (n = 5, 5.4%) and silicosis (n = 5, 5.4%) being the common causes. The CTD-DPLD group had a lower mean age (39.5 ± 1.86 vs 56.9 ± 1.12 years), a longer duration of symptoms (3.5 ± 0.27 vs 2.5 ± 0.26 years), more extra pulmonary manifestations, significantly more base line FVC and 6-minute-walk-distance than the IPF patients. 19 patients of IPF (54%) opted for treatment. All the IPF patients had a significant fall in FVC after six months (mean change -0.203 ± 0.01 litres) compared to the CTD-DPLD group (mean change - 0.05 ± 0.04 litres.) CONCLUSION: CTD-DPLD patients belong to a younger age group, with longer duration of symptoms, more extrapulmonary features, better physiological parameters and better response to therapy than IPF patients. Larger prospective epidemiological studies and enrolment in clinical trials are necessary for better understanding of the spectrum of diffuse parenchymal lung disorders and their therapeutic options. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4220317/ /pubmed/25378843 http://dx.doi.org/10.4103/0970-2113.142115 Text en Copyright: © Lung India http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kundu, Somenath
Mitra, Subhra
Ganguly, Joydeep
Mukherjee, Subhasis
Ray, Souvik
Mitra, Ritabrata
Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience
title Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience
title_full Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience
title_fullStr Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience
title_full_unstemmed Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience
title_short Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience
title_sort spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: an eastern india experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220317/
https://www.ncbi.nlm.nih.gov/pubmed/25378843
http://dx.doi.org/10.4103/0970-2113.142115
work_keys_str_mv AT kundusomenath spectrumofdiffuseparenchymallungdiseaseswithspecialreferencetoidiopathicpulmonaryfibrosisandconnectivetissuediseaseaneasternindiaexperience
AT mitrasubhra spectrumofdiffuseparenchymallungdiseaseswithspecialreferencetoidiopathicpulmonaryfibrosisandconnectivetissuediseaseaneasternindiaexperience
AT gangulyjoydeep spectrumofdiffuseparenchymallungdiseaseswithspecialreferencetoidiopathicpulmonaryfibrosisandconnectivetissuediseaseaneasternindiaexperience
AT mukherjeesubhasis spectrumofdiffuseparenchymallungdiseaseswithspecialreferencetoidiopathicpulmonaryfibrosisandconnectivetissuediseaseaneasternindiaexperience
AT raysouvik spectrumofdiffuseparenchymallungdiseaseswithspecialreferencetoidiopathicpulmonaryfibrosisandconnectivetissuediseaseaneasternindiaexperience
AT mitraritabrata spectrumofdiffuseparenchymallungdiseaseswithspecialreferencetoidiopathicpulmonaryfibrosisandconnectivetissuediseaseaneasternindiaexperience